ROPEGINTERFERON ALFA-2B for thrombocythemia, essential

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Feb 2020: Trial registered, NCT04285086
  2. 25 Aug 2020: Trial started, NCT04285086

The trials

NCT04285086: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

State
Under way
Phase
Phase 3
People
174 taking part
Started
25 Aug 2020
Primary completion
12 Nov 2024
Arms
Ropeginterferon alfa-2b (P1101)
Results
None posted
  1. 26 Feb 2020: Trial registered
  2. 25 Aug 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.